香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SUPERACTIVE GROUP COMPANY LIMITED 先機企業集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：0176） 復牌進度季度更新之 澄清和補充公告 及 繼續暫停買賣 澄清 本公司股東及潛在投資者於投資或買賣本公司證券時務請審慎行事。 承董事會命 董事會謹此澄清於補充公告第二頁第一段中的筆誤，其中本公司股份在 香港聯合交易所有限公司（「聯交所」）主板的交易狀態應為"暫停"，而 非"停止"。 補充資料 茲提述本公司日期為二零二五年十一月十八日之公告（「該公告」），內 容有關（其中包括）授權代表及訴訟代理人的辭職事宜。 1 於陸志強先生辭去根據聯交所證券上市規則（「上市規則」）第 3.05 條委 任的授權代表（「授權代表」）之職務後，授權代表人數不足上市規則第 3.05 條規定的人數。 董事會將盡力委任適當人選擔任授權代表，以重新符合上市規則第 3.05 條之規定。 繼續暫停 ...

Group 1 - The core point of the article is that 易站绿色科技 (08475) has received additional resumption guidance from the Stock Exchange regarding the resumption of trading of its shares due to delays in the publication of its annual results [1] - The company was unable to publish its annual results for the year ending August 31, 2025, by the deadline of November 30, 2025, as required by GEM Listing Rule 18.49, due to the auditor needing extra time to collect and review necessary information for the audit [1] - The Stock Exchange has mandated that the company must publish all outstanding financial results as required by GEM Listing Rules and address any audit revisions before resuming trading [1]

Group 1 - The company *ST Meigu (000615.SZ) announced that its stock will resume trading on December 29, 2025, following the completion of a capital increase plan [1] - The total number of shares increased from 762,979,719 to 1,787,492,693 shares after the issuance of 1,024,512,974 shares [1] - The closing price on the stock's registration date was 4.18 CNY per share, which is higher than the average price of 3.05 CNY per share for the capital increase, leading to an adjusted opening reference price of 3.53 CNY per share on the next trading day [1] Group 2 - The company cautioned investors about the risk of delisting if it fails to execute or cannot execute the reorganization plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Fortune Sun (China) Holdings Limited 富陽（中國）控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：00352） 有關復牌進度的季度最新消息及 繼續暫停買賣 本 公 告 乃 由 富 陽（中 國）控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 根 據 香 港 聯 合 交 易 所 有 限 公 司（「聯交所」）證 券 上 市 規 則（「上市規則」）第13.09條 以及香港法例第571章《證 券 及 期 貨 條 例》第XIVA部 項 下 的 內 幕 消 息 條 文（定 義 見 上 市 規 則）而 作 出。 茲提述本公司(i)日 期 為 二 零 二 五 年 九 月 九 日 之 公 告，內 容 有 關（其 中 包 括）上 市 委 員 會 決 定 維 持 上 市 科 所 作 出 之 ...

Core Viewpoint - *ST Zhengping has announced that its stock will resume trading on December 3, 2025, after completing a review of its trading situation, although it still faces significant risks related to its financial status and potential delisting [1][2] Group 1: Company Overview - *ST Zhengping, officially known as Zhengping Road and Bridge Construction Co., Ltd., is engaged in infrastructure construction, cultural tourism, and non-ferrous metal mining [2] - The company provides services including infrastructure investment consulting, design and construction, operational management, cultural tourism, and mineral resource exploration and development [2] Group 2: Financial Performance - In 2024, *ST Zhengping reported revenue of 1.362 billion yuan and a net loss attributable to shareholders of 484 million yuan [2] - For the first three quarters of 2025, the company achieved revenue of 652 million yuan, a year-on-year decrease of 20.92%, with a net loss attributable to shareholders of approximately 99.76 million yuan [2] Group 3: Stock Performance and Risks - Since September, *ST Zhengping's stock has experienced 26 consecutive trading days of price increases, with a total rise of 221.93% from September 1 to November 18, significantly deviating from the Shanghai Composite Index and the construction industry [1] - The rapid increase in stock price has led to heightened trading risks, prompting the company to suspend trading for review on November 19, 2025 [1]

Core Viewpoint - The company announced that its stock will resume trading on December 3, 2025, after completing a recent review of stock trading activities [1] Group 1: Stock Trading and Market Conditions - The company's price-to-earnings (P/E) ratio and price-to-book (P/B) ratio are significantly higher than the industry average [1] - There is a relatively small external circulation of shares, which may lead to irrational speculation risks [1] Group 2: Control Change and Uncertainties - There is uncertainty regarding the change of control of the company, with questions surrounding the approval process and the timeline for approval [1]

Core Viewpoint - *ST Zhengping (603843) announced that its stock will resume trading on December 3 after completing a review of its trading situation, although it still faces significant uncertainties regarding its financial status and potential restructuring [1] Group 1: Stock Trading and Resumption - The company has completed the necessary review of its stock trading situation and has applied to the Shanghai Stock Exchange for resumption of trading [1] - The stock is set to resume trading on December 3 [1] Group 2: Financial Status and Audit Opinions - As of now, the company has not resolved the non-standard audit opinion for the fiscal year 2024 [1] - If the issues related to the non-standard opinion are not resolved by the fiscal year 2025, the company’s stock may face delisting [1] Group 3: Restructuring and Legal Proceedings - Recently, creditors have applied for the company’s pre-restructuring, but the company has not yet received any legal documents from the court regarding the acceptance of this application [1] - There is significant uncertainty regarding whether the court will accept the pre-restructuring application and whether the company will enter the restructuring process [1]

Core Viewpoint - TATA Health (01255) has resumed trading after more than 1.5 years, experiencing a significant price surge of over 500% in early trading, reaching HKD 1.86 with a trading volume of HKD 6.33 million [1] Summary by Relevant Sections - **Resumption of Trading** - TATA Health has successfully met all resumption guidelines, allowing it to resume trading after a prolonged suspension [1] - **Financial Performance and Compliance** - The company has published all outstanding financial results and addressed any audit revisions, ensuring compliance with regulatory requirements [1] - **Business Viability** - TATA Health confirmed that its business operations are sustainable, with sufficient operational capacity and valuable assets to support ongoing business activities [1] - **Internal Controls** - An independent internal control review has been conducted, demonstrating that the company has established adequate internal controls and procedures to fulfill its responsibilities under listing rules [1]

Group 1 - The company announced that its stock will resume trading on November 21, 2025, following the completion of relevant verification work [1] - The company's current rolling price-to-earnings ratio and price-to-book ratio show significant differences compared to industry peers [1] - The company's main business has not undergone significant changes, but there is a risk of market sentiment overheating and irrational speculation due to a recent continuous rise in stock price [1]

Core Viewpoint - The company, HeFu China, announced that its stock will resume trading on November 20, 2025, after a significant price increase during the trading suspension period [1] Summary by Relevant Sections Stock Performance - From October 28 to November 14, the company's stock experienced a remarkable performance, with 12 out of 14 trading days closing at the daily limit price, resulting in a total increase of 256.29%, significantly outperforming the industry and the Shanghai Composite Index [1] Financial Status - The company's main business remains unchanged; however, it is currently operating at a loss, with a net profit attributable to shareholders of -5.048 million yuan in the third quarter of 2025 [1] - The latest price-to-earnings (P/E) ratio stands at 343.67, which is considerably higher than that of peer companies in the industry [1] Investor Advisory - The company has advised investors to be aware of performance volatility and the risks associated with high valuation, urging rational investment and caution regarding trading risks [1]